Eplerenone improves clinical stability in patients hospitalized with acute heart failure: Study
Japan: Treatment with eplerenone improves clinical stability, especially during the short period after hospitalization for acute HF (AHF); this is the key finding from a study featured in the International Journal of Cardiology.
The clinical stability was shown by the lower diuretic doses (both in-hospital and out-of-hospital settings), decreased natriuretic peptide levels, and improved echocardiographic markers of congestion and LV volume. Higher diuretic doses were linked with a risk of HF-related events and more severe congestion.
Eplerenone was not shown to reduce all-cause mortality or heart failure hospitalizations in 300 patients admitted for acute heart failure in the EARLIER (Efficacy and Safety of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure) trial. The trial, however, might have been underpowered for these endpoints, and a comprehensive overview of eplerenone's effect on the clinical stability of the patient and diuretic disease is warranted.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.